These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14331)

  • 41. Behavioral pharmacologic studies in the monkey with DD-3480.
    Shibuya T; Nishimori T; Matsuda H; Chen PC
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM; Wauquier A
    Arzneimittelforschung; 1975 Aug; 25(8):1287-94. PubMed ID: 1242360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
    Noda Y; Kurumiya S; Miura Y; Oka M
    J Pharmacol Exp Ther; 1993 May; 265(2):745-51. PubMed ID: 8098763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavioral patterns related to dopamine neurotransmission: effect of acute and chronic antipsychotic drugs.
    Ungerstedt U; Ljungberg T
    Adv Biochem Psychopharmacol; 1977; 16():193-9. PubMed ID: 18882
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuroleptics attentuate stereotyped behavior induced by beta-phenylethylamine in rats.
    Moja EA; Stoff DM; Gillin JC; Wyatt RJ
    Biol Psychiatry; 1978 Apr; 13(2):291-5. PubMed ID: 566570
    [No Abstract]   [Full Text] [Related]  

  • 46. Neuropharmacological and neurochemical approaches to preclinical evaluation of neuroleptics.
    Zakusov VV
    Adv Biochem Psychopharmacol; 1980; 24():295-303. PubMed ID: 6105781
    [No Abstract]   [Full Text] [Related]  

  • 47. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors.
    Van Rossum JM
    Mod Probl Pharmacopsychiatry; 1970; 5():65-7. PubMed ID: 5527171
    [No Abstract]   [Full Text] [Related]  

  • 49. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemical and pharmacological classification of neuroleptics.
    Janssen PA
    Mod Probl Pharmacopsychiatry; 1970; 5():33-44. PubMed ID: 5535847
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug-induced changes of dopamine turnover in striatum and limbic system of the rat.
    Bartholini G; Keller HH; Pletscher A
    J Pharm Pharmacol; 1975 Jun; 27(6):439-42. PubMed ID: 237095
    [No Abstract]   [Full Text] [Related]  

  • 52. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 53. [Central effects of some adreno- and-or sympatholytic substances. 3. Ptosis, catalepsy, antagonism with respect to apomorphine and amphetamine].
    Boissier JR; Simon P; Giudicelli JF
    Arch Int Pharmacodyn Ther; 1968 Jan; 171(1):68-80. PubMed ID: 5689547
    [No Abstract]   [Full Text] [Related]  

  • 54. Influence of neuroleptic drugs and apomorphine on dopamine-sensitive adenylate cyclase of retina.
    Brown JH; Makman MH
    J Neurochem; 1973 Aug; 21(2):477-9. PubMed ID: 4353338
    [No Abstract]   [Full Text] [Related]  

  • 55. Potentiation and inhibition of the amphetamine stereotypy in rats by neuroleptics and other agents.
    Lal S; Sourkes TL
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):289-301. PubMed ID: 4672248
    [No Abstract]   [Full Text] [Related]  

  • 56. A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs.
    Jenner P; Clow A; Reavill C; Theodorou A; Marsden CD
    Life Sci; 1978 Aug; 23(6):545-9. PubMed ID: 692279
    [No Abstract]   [Full Text] [Related]  

  • 57. The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity.
    Klawans HL; D'amico DJ; Nausieda PA; Weiner WJ
    Psychopharmacology (Berl); 1977 Nov; 55(1):49-52. PubMed ID: 414261
    [No Abstract]   [Full Text] [Related]  

  • 58. Possible anomalous behaviour of apomorphine in relation to other dopamine receptor agonists.
    Feenstra MG; Goedemoed JH; Rollema H; Horn AS
    J Pharm Pharmacol; 1983 Jul; 35(7):471-3. PubMed ID: 6136595
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of apomorphine on motility in rats.
    Maj J; Grabowska M; Gajda L
    Eur J Pharmacol; 1972 Feb; 17(2):208-14. PubMed ID: 5026397
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of the behavioral depressant effects of biogenic amine depleting and neuroleptic agents following various 6-hydroxydopamine treatments.
    Cooper BR; Grant LD; Breese GR
    Psychopharmacologia; 1973 Jul; 31(2):95-109. PubMed ID: 4722209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.